{"id":"hydrochlorothiazide-potassium","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia (mitigated by potassium supplementation)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Ototoxicity (at high doses)"}]},"_chembl":{"chemblId":"CHEMBL435","moleculeType":"Small molecule","molecularWeight":"297.75"},"_dailymed":{"setId":"d838e918-2463-79f6-e053-2a95a90a948d","title":"LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLET, FILM COATED [DIRECT RX]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrochlorothiazide is a thiazide diuretic that blocks the sodium-chloride cotransporter in the kidney's distal convoluted tubule, promoting sodium and water excretion and reducing blood volume and vascular resistance. However, thiazides increase urinary potassium loss, which can lead to hypokalemia; the addition of potassium supplementation maintains normal serum potassium levels and prevents cardiac arrhythmias and muscle weakness associated with potassium depletion.","oneSentence":"Hydrochlorothiazide reduces blood pressure by inhibiting sodium reabsorption in the distal convoluted tubule, while potassium supplementation counteracts the potassium-wasting effects of the thiazide diuretic.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:34:29.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease"}]},"trialDetails":[{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT01149473","phase":"PHASE1","title":"Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-03","conditions":"Healthy","enrollment":80},{"nctId":"NCT00398541","phase":"PHASE3","title":"Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-03-01","conditions":"Hypertension","enrollment":41},{"nctId":"NCT00307060","phase":"PHASE3","title":"MK0954A-264 Filter Study (0954A-264)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-01","conditions":"Mild to Severe Hypertension","enrollment":274},{"nctId":"NCT00480805","phase":"PHASE3","title":"HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-08-08","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":312},{"nctId":"NCT00400218","phase":"PHASE3","title":"Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension","enrollment":62},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00449111","phase":"PHASE3","title":"An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-03-13","conditions":"Hypertension","enrollment":11},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00546052","phase":"PHASE3","title":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09-01","conditions":"Hypertension, Metabolic Disorder","enrollment":1738},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT00739674","phase":"PHASE3","title":"SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":992},{"nctId":"NCT00896389","phase":"PHASE4","title":"Salt Loading and Thiazide Intervention Study","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-10","conditions":"Hypertension","enrollment":124},{"nctId":"NCT00092209","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-04","conditions":"Hypertension","enrollment":840},{"nctId":"NCT01368185","phase":"","title":"Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypertension","enrollment":1705},{"nctId":"NCT00953680","phase":"PHASE1","title":"Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":"Hypertension","enrollment":77},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT02824718","phase":"PHASE2","title":"Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-06","conditions":"Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment","enrollment":16},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":"Acute Heart Failure, Acute Kidney Injury","enrollment":100},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT01102478","phase":"NA","title":"Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-02","conditions":"Hypertension","enrollment":30},{"nctId":"NCT01102465","phase":"NA","title":"Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2005-02","conditions":"Hypertension","enrollment":25},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT01218724","phase":"PHASE1","title":"Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01218711","phase":"PHASE1","title":"Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00865124","phase":"NA","title":"Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Vascular Disease","enrollment":69},{"nctId":"NCT00354991","phase":"PHASE3","title":"Hyzaar Asia HEAALTH (0954A-950)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-01","conditions":"Hypertension","enrollment":437},{"nctId":"NCT02900729","phase":"PHASE3","title":"Randomized Controlled Trial of Renal Denervation for Resistant Hypertension","status":"UNKNOWN","sponsor":"Shanghai WiseGain Medical Devices Co., Ltd.","startDate":"2016-10","conditions":"Hypertension","enrollment":254},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT00000525","phase":"PHASE3","title":"Diuretics, Hypertension, and Arrhythmias Clinical Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1986-07","conditions":"Cardiovascular Diseases, Death, Sudden, Cardiac, Heart Arrest","enrollment":233},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":"Kidney Disease","enrollment":24},{"nctId":"NCT01392534","phase":"","title":"Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-07","conditions":"Primary Hypertension","enrollment":1586},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT01149486","phase":"PHASE1","title":"Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT00605202","phase":"PHASE4","title":"Effect of Licorice and Hydrochlorothiazide on Plasma Potassium","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2008-02","conditions":"Hypokalemia","enrollment":10},{"nctId":"NCT00617877","phase":"NA","title":"Antihypertensive Response to Losartan and Genetic Polymorphisms","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hypertension","enrollment":800},{"nctId":"NCT00214825","phase":"NA","title":"Aldosterone and Vascular Disease in Diabetes Mellitus","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-08","conditions":"Diabetes Mellitus, Endothelial Dysfunction, Albuminuria","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrochlorothiazide + potassium","genericName":"Hydrochlorothiazide + potassium","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrochlorothiazide reduces blood pressure by inhibiting sodium reabsorption in the distal convoluted tubule, while potassium supplementation counteracts the potassium-wasting effects of the thiazide diuretic. Used for Hypertension, Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}